Vir Biotechnology Inc (NASDAQ:VIR) price on Thursday, February 27, fall -11.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.11.
A look at the stock’s price movement, the close in the last trading session was $9.20. Turning to its 52-week performance, $14.45 and $6.56 were the 52-week high and 52-week low respectively. Overall, VIR moved -23.42% over the past month.
Vir Biotechnology Inc’s market cap currently stands at around $1.12 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 3.58M for the company’s revenue for the quarter, with a low and high estimate of 2.15M and 5M respectively. The average forecast suggests down to a -93.66% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 32.2M, representing a -56.60% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VIR is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 7 recommend VIR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VIR’s current price about -15.56% and -12.17% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.15, while 7-day volatility ratio is 8.58% and 6.59% in the 30-day chart. Further, Vir Biotechnology Inc (VIR) has a beta value of 1.15, and an average true range (ATR) of 0.69. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. Looking at the price targets, the low is -146.61% off current price level while to achieve the yearly target high, price needs to move -146.61%. Nonetheless, investors will most likely welcome a -146.61% jump to $20 which is the analysts’ median price.
If we refocus on Vir Biotechnology Inc (NASDAQ:VIR), historical trading data shows that trading volumes averaged 2.10 million over the past 3 months. The company’s latest data on shares outstanding shows there are 136.96 million shares.
The 36.05% of Vir Biotechnology Inc’s shares are in the hands of company insiders while institutional holders own 51.17% of the company’s shares. Current price change has pushed the stock 10.49% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VIR stock continues to rise going into the next quarter.
